中文名稱:喜樹堿 | 英文名稱:Camptothecin |
CAS:7689-03-4 | 品牌: TargetMol |
產地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.52% | 產品類別: 抑制劑 |
貨號: T1123 |
名稱 | Camptothecin |
描述 | Camptothecin (CPT) belongs to the alkaloid group of natural products and is a specific DNA topoisomerase I (Topo I) inhibitor (IC50=679 nM) with specificity. Camptothecin has antitumor activity and induces apoptosis. |
細胞實驗 | Tumor cells are plated in 100 μL of medium in 96-well microtiter plates at a density of 1500 to 4000 cells per well and allowed to adhere overnight. Cells are incubated with Camptothecin for 48 hours and then with fresh medium for 48 hours. Camptothecin at each concentration is added in quadruplicate. Following a 4-hour incubation of treated cells with MTT, the reduced dye product is extracted from the cells with 0.2 mL of DMSO followed by 50 μL of Sorensen's buffer. The plates are shaken briefly, and the absorbance at 570 nm is read and quantitated. Curves are fitted to the MTT assay data using a four-parameter logistic equation.(Only for Reference) |
激酶實驗 | Topoisomerase I Cleavable Complex Assay: Topoisomerase I is isolated from calf thymus and is devoid of topoisomerase II. All reactions are carried out in 10 mL volumes of reaction buffer (50 mM Tris-HCl, pH 7.5, 100 mM KCl, 0.5 mM EDTA, and 30 pg/mL BSA) in microtiter plates. Camptothecin is dissolved in DMSO at 10 mg/mL and serially diluted in 96-well microtiter plates to which the 32P end-labeled pBR322 DNA and topoisomerase enzyme are added. The reaction mixture is incubated at room temperature for 30 min and then the reaction stopped by adding 2 mL of a mixture of sodium dodecyl sulfate and proteinase K (1.6% and 0.14 mg/mL final concentrations, respectively). The plates are heated at 50 °C for 30 min, 10 mL of standard stop mixture containing 0.45 N NaOH is added in order to generate single-stranded DNA, and the samples are electrophoresed in 1.5% agarose gels in TBE buffer. Gels are blotted on nitrocellulose paper, dried, and exposed to X-ray film. The units of cleavage are calculated from the autoradiographs and plotted against the log drug concentration. The IC50 values are then obtaine |
體外活性 | 方法:八株 TNBC 細胞系用 Camptothecin (0.1-5 μM) 處理 72 h,使用 PrestoBlue 檢測細胞活力。 結果:Camptothecin 抑制 MCF7、HCC1428、HCC1419、HCC202、MDA453、MDA231、Sum149、BT549 細胞活力,IC50 值分別為 0.089/0.448/0.067/0.481/0.058/0.040/0.065/0.056 μM。[1] 方法:肺癌細胞 H1299 和 H460 用 Camptothecin (0.5-5 μM) 處理 16 h,使用 wound-healing assay 檢測細胞遷移情況。 結果:Camptothecin 抑制 H1299 和 H460 細胞遷移,但沒有劑量依賴性作用。[2] |
體內活性 | 方法:為檢測體內抗腫瘤活性,將 Camptothecin (0.15-1.2 mg/kg) 和 doxorubicin (0.25-2 mg/kg) 靜脈注射給攜帶三陰性乳腺癌腫瘤 MDA-MB-231 的 athymic nu/n 小鼠,每兩天一次,給藥四次。 結果:觀察到腫瘤生長的劑量依賴性減少,在 0.5 mg/kg DOX + 0.3 mg/kg CPT 下減少 40.8% ,在 1.5 mg/kg DOX + 0.9 mg/kg CPT 下減少 93%。最高的測試劑量 (2 mg/kg DOX + 1.2 mg/kg CPT) 在第 44 天完全停止了腫瘤的生長。[3] 方法:為研究對肥胖的作用,將 Camptothecin (1 mg/kg,0.1% Tween 80) 口服給藥給肥胖小鼠,每天一次,持續(xù)三天。 結果:口服 Camptothecin 可增加飲食誘導肥胖 (DIO) 小鼠和遺傳 ob/ob 小鼠的循環(huán) GDF15 水平。與 GDF15 的厭食作用一致,Camptothecin 抑制食物攝入,從而降低肥胖小鼠的體重、血糖和肝臟脂肪含量。[4] |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 0.5 mg/mL (1.44 mM), Suspension. Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. DMSO : 3.48 mg/mL (10 mM) |
關鍵字 | Apoptosis | NSC100880 | HIF-1α | Inhibitor | Antibiotic | ADC Payload | DNA topoisomerase I | microRNAs | NSC 100880 | Top1 | miRNA | inhibit | Camptothecin | Topoisomerase | alkaloid | miRN | Influenza Virus | MicroRNA | Fungal | ADC Cytotoxin |
相關產品 | L-Glutamic acid | Dehydroacetic acid sodium | Doxycycline | Neomycin sulfate | Geraniol | Dextran sulfate sodium salt (MW 4500-5500) | Stavudine | Ampicillin sodium | L-Ascorbic acid | Sulfamethoxazole sodium | Kanamycin sulfate | Sodium 4-phenylbutyrate |
相關庫 | 經典已知活性庫 | 抗癌活性化合物庫 | 生物堿類天然產物庫 | 天然產物庫 | 藥物功能重定位化合物庫 | 抗癌臨床化合物庫 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.2651萬人民幣 |
員工人數 | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 化學試劑,生物活性小分子 | 經營模式 | 貿易,試劑,定制,服務 |
產品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP6年
|
湖北威德利化學試劑有限公司
|
2025-02-25 | |
詢價 |
VIP5年
|
武漢鼎信通藥業(yè)有限公司
|
2025-02-25 | |
詢價 |
VIP1年
|
湖北鴻福達生物科技有限公司
|
2025-02-25 | |
詢價 |
VIP2年
|
臺州開創(chuàng)生物醫(yī)藥有限公司
|
2025-02-25 | |
詢價 |
VIP5年
|
武漢華玖醫(yī)藥科技有限公司
|
2025-02-25 | |
詢價 |
VIP6年
|
湖北阡陌生物科技有限公司
|
2025-02-25 | |
詢價 |
VIP6年
|
湖北鴻福達生物科技有限公司
|
2025-02-25 | |
¥450 |
VIP8年
|
長沙上禾生物科技有限公司
|
2025-02-25 | |
¥25000 |
VIP5年
|
武漢克米克生物醫(yī)藥技術有限公司
|
2025-02-25 | |
詢價 |
VIP12年
|
深圳振強生物技術有限公司
|
2025-02-25 |